Influenza Vaccine Market to Reach $17.41 Billion by 2035, Growing at 7.72% CAGR | Sanofi, GSK, Pfizer Lead Global Competition

The global influenza vaccine market, valued at USD 8.27 billion in 2025, is on track to reach USD 17.41 billion by 2035, advancing at a compound annual growth rate (CAGR) of 7.72% over the forecast period. Seasonal flu infects roughly one billion people every year worldwide, and the persistent threat of pandemic strains is compelling governments, health agencies, and pharmaceutical companies to expand vaccination infrastructure at a scale the industry has not seen in the previous decade. The numbers signal a market that is not simply recovering from a post-COVID plateau but is building structural, sustained momentum.

To explore the complete findings and methodology behind this forecast, request a free sample of the report at https://www.rootsanalysis.com/reports/influenza-vaccine-market/request-sample.html

Market Overview
Influenza is a highly contagious acute respiratory illness caused by influenza A and B viruses. According to the World Health Organization, between 3 and 5 million cases each year result in severe illness, and approximately 650,000 deaths are attributable to respiratory complications. In developing nations, the toll is especially acute among young children: 99% of influenza-related lower respiratory tract infection deaths in those countries occur in children under the age of five. The sheer breadth of that public health burden creates a consistent, year-round commercial market for influenza vaccines across every income bracket and geography.

Two categories of vaccines dominate clinical practice. Inactivated influenza vaccines, which contain killed viral particles, are approved for all age groups including immunocompromised patients and are the backbone of most national immunization programs. Live attenuated influenza vaccines, administered as a nasal spray, are gaining traction particularly in pediatric settings. Both categories are evolving rapidly: cell-based and recombinant production platforms are displacing traditional egg-based manufacturing, and mRNA technology, validated during the COVID-19 era, is now being applied to influenza with serious government capital behind it.

Government funding is a significant accelerant. In January 2025, the United States government allocated an additional USD 590 million to Moderna to fast-track its mRNA-based H5N1 avian influenza vaccine. That single investment underscores how pandemic preparedness has become a national security priority, not merely a public health agenda item. Similar dynamics are playing out in Asia and Europe, where health ministries are funding procurement programs, running awareness campaigns, and actively expanding cold chain infrastructure to reach rural populations.

Key Growth Drivers
Rising Global Burden of Influenza Infections. Seasonal outbreaks create a predictable, recurring demand that gives manufacturers reliable revenue visibility. The memory of the H1N1 pandemic in 2009 and ongoing concerns about H5N1 spillover events continue to keep governments on high alert, accelerating procurement pipelines and creating surge capacity contracts that sustain market volume beyond routine seasonal cycles.

Government Funding and Pandemic Preparedness Programs. Public health agencies across North America, Europe, and Asia are not simply recommending flu vaccination; they are actively subsidizing it. Mass immunization campaigns, healthcare worker mandates, and school-based vaccination programs are driving consistent uptake. The US government's USD 590 million investment in mRNA influenza vaccine development in early 2025 is the most visible recent example of how strategic government capital is reshaping the competitive and technological terrain.

mRNA and Next-Generation Vaccine Technologies. The success of mRNA platforms during the COVID-19 pandemic opened a direct pathway to applying that technology to influenza. Cell-based production, which grows the virus in mammalian cell cultures rather than eggs, eliminates a key supply chain vulnerability and accelerates manufacturing timelines. Cell-based production is forecast to grow at 10.5% CAGR through 2035, outpacing the established egg-based segment. These platforms are attracting both government grants and private venture capital at a rate that will materially shift the competitive composition of the market within the forecast window.

Quadrivalent Vaccine Adoption Displacing Trivalent Formulations. Quadrivalent vaccines protect against two lineages of both influenza A and influenza B, which trivalent vaccines do not. That broader coverage reduces the risk of strain mismatch and is increasingly the standard recommended by WHO and national health authorities. In March 2024, India-based Cadila Pharmaceuticals launched Cadiflu Tetra, a quadrivalent product approved by India's Drug Controller General, illustrating how demand for four-strain coverage is penetrating emerging markets, not just established ones.

Expanding Retail Pharmacy Access. Hospital pharmacies currently hold about 39% market share in distribution, but retail pharmacies are the fastest-growing channel, forecast to expand at an 11.58% CAGR through 2035. Retail access removes the requirement for a clinical appointment, which meaningfully increases vaccination rates among working-age adults. The FDA's September 2024 approval of FluMist for self-caregiver administration without a prescription is a structural shift that will accelerate this channel further.

Market Segmentation
The influenza vaccine market organizes across five primary dimensions: vaccine type, valency, age group, production technology, and distribution channel. Inactivated vaccines hold approximately 66% of the vaccine type segment and will retain that lead through 2035, driven by their universal approval across age and risk groups. However, live attenuated vaccines are the faster-growing sub-segment, forecast at a 9.65% CAGR, as nasal spray delivery gains acceptance in pediatric programs.

Among age groups, adults represent roughly 43% of current market share and remain the dominant cohort. The pediatric segment is the fastest growing within this dimension, at a projected 10.14% CAGR, reflecting heightened attention to childhood immunization given that children under five face disproportionate complication risk. In terms of production technology, egg-based methods still account for about 65% of market share, but cell-based production is rising quickly at 10.5% CAGR, supported by its faster timelines and elimination of the egg supply dependency that complicates pandemic response. The quadrivalent valency segment is forecast to hold 63% of revenue by 2035, while trivalent formulations grow at a more moderate 7.81% rate.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/influenza-vaccine-market/request-quote.html

Regional Insights
North America commands approximately 47% of the current global influenza vaccine market and is projected to maintain that lead through 2035. The United States and Canada have mature, well-funded public health systems with widespread influenza vaccination programs backed by strong recommendations from the CDC and Health Canada. In July 2024, GSK shipped trivalent influenza vaccine doses to US healthcare providers and pharmacies ahead of the 2024-25 flu season, illustrating the depth and reliability of distribution infrastructure in the region. High per-capita healthcare expenditure, a concentrated base of major manufacturers, and robust clinical trial activity collectively reinforce North America's position.

Asia is the fastest-growing region in the influenza vaccine market, forecast to expand at an 11.87% CAGR through 2035. Rapid urbanization in China, India, and Southeast Asia is increasing population density in major cities, which directly amplifies the risk of influenza transmission and drives demand for systematic vaccination. Government and private sector investment in vaccination programs across the region is accelerating. In August 2024, Apollo Clinic launched a nationwide seasonal flu vaccination campaign across 102 clinics in India, providing a concrete illustration of how institutional momentum in Asia is translating into market volume. Europe maintains a significant market presence, supported by universal healthcare systems and mandatory healthcare worker vaccination policies in several member states.

Competitive Landscape
Leading companies active in the influenza vaccine market include Sanofi (France), GlaxoSmithKline (UK), AstraZeneca (UK), Pfizer (US), Merck (US), Novartis (Switzerland), F. Hoffmann-La Roche (Switzerland), Boehringer Ingelheim International (Germany), Shionogi (Japan), Sinovac (China), OSIVAX (France), Bristol-Myers Squibb (US), Mylan NV (US), and Viatris (US), among others.

The market is defined by established global pharmaceutical leaders who dominate through scale, regulatory relationships, and multi-country distribution networks. Competition centers on vaccine efficacy data, speed of strain-matched production, and geographic reach rather than on price alone. Biotechnology challengers, particularly those advancing mRNA and cell-based platforms, are attracting government contracts that could meaningfully shift market share over the back half of the forecast period. Strategic partnerships, licensing agreements, and expanded manufacturing capacity in emerging markets are the primary battlegrounds as incumbents work to defend positions while newer entrants compete for next-generation platform dominance. In February 2025, Zydus Lifescience introduced a quadrivalent influenza vaccine based on WHO-recommended composition, signaling that emerging market manufacturers are moving beyond generic replication into formulation innovation.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/influenza-vaccine-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.